Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00813748 · ClinicalTrials.gov registry record
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
A clinical trial of Allergic Asthma, sponsored by Genentech.
- Completed
- Registry status
- 118
- Enrollment target
- 7
- Study locations
NCT00813748 is a study of Allergic Asthma that has completed, run by Genentech. The registered enrollment target is 118 participants, below the 176-participant average among 4 other Allergic Asthma trials with a reported enrollment target (33% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT00813748, a study of Allergic Asthma, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 118 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will establish a clinical data and serum repository of anaphylaxis cases associated with Xolair administration and control patients who have received Xolair without associated anaphylaxis. This is an observational repository and not an investigational clinical trial. Associated with the repository is an optional skin testing substudy.
Conditions Studied
Interventions
- DRUG Xolair
Study Locations (7)
California
- Investigational Site - Los Angeles
Florida
- Investigational Site - Valrico
Illinois
- Investigational Site - Hinsdale
Missouri
- Investigational Site - Kansas City
New York
- Investigational Site - New York
Pennsylvania
- Investigational Site - Blue Bell
Texas
- Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2009-03 |
| Est. Completion | 2014-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00813748
The ClinicalTrials.gov registry entry for NCT00813748 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 176-participant average among 4 other Allergic Asthma trials with a reported enrollment target (33% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Asthma appearing as the primary indexed condition, and to 1 intervention - of which Xolair is the first listed.
NCT00813748 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00813748 about?
NCT00813748 is a clinical study titled "Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing". This study will establish a clinical data and serum repository of anaphylaxis cases associated with Xolair administration and control patients who have received Xolair without associated anaphylaxis. This is an observational repository and not an investigational clinical trial. Associated with the r...
What is the current status of trial NCT00813748?
This trial is currently completed. The enrollment target is 118 participants. The study started on 2009-03. Estimated completion is 2014-01.
What conditions does trial NCT00813748 study?
This clinical trial studies the following conditions: Allergic Asthma.
What interventions are being tested in trial NCT00813748?
The interventions under investigation include: Xolair (DRUG).
Who is sponsoring clinical trial NCT00813748?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00813748 being conducted?
This trial has 7 study locations across California, Florida, Illinois, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)
RECRUITING · Phase 3
-
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
COMPLETED · Phase 4
-
Characterization of the Role of Histamine in Children With Asthma
COMPLETED · Phase 2
-
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.